Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Czech Lymphoma Study Group
With
Ministry of Health, Czech Republic
This is an observational study considered for patients with mantle cell lymphoma meeting the basic inclusion criteria. The study will enrol patients who will be treated according to standard protocol used in the hematologic department. Scheme of treatment: alternating cycles of R-CHOP and R-AraC: R-CHOP / R-AraC / R-CHOP / R-AraC / R-CHOP / R-AraC.
Baseline procedures:
* CT or PET-CT (positron emission tomography with computed tomography)before starting treatment, after 3 cycles and at the end of treatment (after 6 cycles)
* bone marrow examination before therapy, after 3 cycles and after completion of induction
* maintenance rituximab based of standards of each centre
The study was proposed based on the previously published data in the younger patients, which demonstrated improved outcome after implementation of Ara-C into induction.
Primary objectives include response after induction by PET-CT and PFS (progression-free survival).
Secondary objectives include OS (overall survival), and prognostic significance of minimal residual disease detection after completion of induction
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
confirmed diagnosis of MCL (hematopathologic examination in the reference centre, with evidence of cyclin D1 or translocation t(11;14) )
You may not be if
eligible for R-CHOP or R-COEP-based therapy
signed informed consent form with the study and data processing
non compliance of a patient
CNS (central nervous system) involvement with lymphoma
ECOG (Eastern Cooperative Oncology Group) \>3 or active uncontrolled comorbidities